NXTC · Nextcure Inc
United States · RS rating 51 · As of 2026-11-03
| Price | 5.91 USD |
|---|---|
| 1-day change | +3.8% |
| RS rating (overall / 1M / 3M / 12M) | 51 / 91 / 84 / 20 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 21 / 16 / 30 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -49.7% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +58.6% |
| Market cap (USD) | $44.1M |